Zevra Therapeutics, Inc. Payments to Acquire Other Investments
Zevra Therapeutics, Inc. (ZVRA) reported Payments to Acquire Other Investments of $80.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireOtherInvestments · last filed 2026-08-05
- Zevra Therapeutics, Inc. payments to acquire other investments for the quarter ending 2026-06-30 was $22.54M, a 85.01% decline year-over-year.
- Zevra Therapeutics, Inc. payments to acquire other investments for the quarter ending 2026-03-31 was $58.30M, a 692.17% increase year-over-year.
- Zevra Therapeutics, Inc. payments to acquire other investments for the quarter ending 2025-12-31 was $87.16M.
- Zevra Therapeutics, Inc. payments to acquire other investments for the quarter ending 2025-09-30 was $65.11M, a 57.43% increase year-over-year.
- Zevra Therapeutics, Inc. payments to acquire other investments for fiscal 2025 was $309.99M, a 653.11% increase from fiscal 2024.
- Zevra Therapeutics, Inc. payments to acquire other investments for fiscal 2024 was $41.16M, a 10.16% decline from fiscal 2023.
- Zevra Therapeutics, Inc. payments to acquire other investments for fiscal 2023 was $45.81M.
| Period end | Payments to Acquire Other Investments 3 month | Payments to Acquire Other Investments 6 month | Payments to Acquire Other Investments 9 month | Payments to Acquire Other Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $80.84M 10-Q · filed 2026-08-05 | $168.00M derived: sum of 3 quarters · filed 2026-08-05 | $233.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $58.30M 10-Q · filed 2026-05-06 | $145.46M derived: sum of 2 quarters · filed 2026-05-06 | $210.57M derived: sum of 3 quarters · filed 2026-05-06 | $360.92M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $87.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $152.27M derived: sum of 2 quarters · filed 2026-03-09 | $302.63M derived: sum of 3 quarters · filed 2026-08-05 | $309.99M 10-K · filed 2026-03-09 |
| 2025-09-30 | $65.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $215.46M derived: sum of 2 quarters · filed 2026-08-05 | $222.82M 10-Q · filed 2025-11-05 | $222.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $150.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $157.71M 10-Q · filed 2026-08-05 | $157.38M derived: sum of 3 quarters · filed 2026-08-05 | $198.74M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $7.36M 10-Q · filed 2026-05-06 | $7.03M derived: sum of 2 quarters · filed 2026-05-06 | $48.39M derived: sum of 3 quarters · filed 2026-05-06 | $48.52M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$327.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $41.03M derived: sum of 2 quarters · filed 2026-03-09 | $41.16M derived: sum of 3 quarters · filed 2026-03-09 | $41.16M 10-K · filed 2026-03-09 |
| 2024-09-30 | $41.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $41.49M derived: sum of 2 quarters · filed 2025-11-05 | $41.49M 10-Q · filed 2025-11-05 | $41.48M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $129.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $129.00K 10-Q · filed 2025-08-12 | $122.00K derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | -$7.00K derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $45.81M 10-K · filed 2025-03-12 | ||
| 2023-09-30 | $45.82M 10-Q · filed 2024-11-13 | |||
| 2022-09-30 | $23.83M 10-Q · filed 2023-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |